Proliferative lifespan checkpoints: Cell-type specificity and influence on tumour biology

European Journal of Cancer Part A

Volumn 33, Issue 5, 1997, Pages 716-726

  Wynford Thomas, D ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

immortalisation; p53; pRb; senescence; tumour suppressor genes

Indexed keywords

ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL SPECIFICITY; CELL SURVIVAL; CELL TYPE; GROWTH REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL AGING; GENES, TUMOR SUPPRESSOR; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030917098     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00064-6     Document Type: Article

References (87)

1. Leblond CP. Classification of cell populations on the basis of their proliferative capacity. Natl Cancer Inst Monogr 1964, 14, 119-149.
2. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37, 614-636.
3. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995, 5, 293-297.
4. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalisation of normal human diploid fibroblasts. Mol Cell Biol 1989, 9, 3088-3092.
5. Olovnikov AM. A theory of marginotomy: the incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973, 41, 181-190.
6. Bacchetti S. Telomere dynamics and telomerase activity in cell senescence and cancer. Semin Cell Dev Biol 1996, 7, 31-39.
7. Wynford-Thomas D. In vitro models of thyroid cancer. Cancer Surveys 1993, 16, 115-134.
8. Potten CS, Loeffler M. Stem-cells - attributes, cycles, spirals, pitfalls and uncertainties - lessons for and from the crypt. Development 1990, 110, 1001-1020.
9. Broccoli D, Young JW, De Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995, 92, 9082-9086.
10. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995, 85, 2315-2320.
11. Potten CS, Hume WJ, Reid P, Cairns J. The segregation of DNA in epithelial stem cells. Cell 1978, 15, 899-906.
12. Goldstein S. Replicative senescence: the human fibroblast comes of age. Science 1990, 249, 1129-1132.
13. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994, 211, 90-98.
14. CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996, 16, 859-867.
15. Bryan TM, Reddel RR. SV40-induced immortalization of human cells. Crit Rev Oncol 1994, 5, 331-357.
16. Shay JW, Wright WE, Brasiskyte D, Van der Hagen BA. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalisation in human mammary epithelial cells but not human fibroblasts. Oncogene 1993, 8, 1407-1413.
17. Bond JA, Wyllie FS, Wynford-Thomas D. Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 1994, 9, 1885-1889.
18. ink4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995, 15, 4745-4753.
19. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. BioEssays 1995, 17, 501-508.
20. Thut CJ, Chen J-L, Klemm R, Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995, 267, 100-105.
21. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994, 370, 220-223.
22. Sabbatini P, Chiou S-K, Rao L, White E. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol 1995, 15, 1060-1070.
23. Cox LS, Hupp T, Midgley CA, Lane DP. A direct effect of activated human p53 on nuclear DNA replication. EMBO J 1995, 14, 2099-2105.
24. Frebourg T, Barbier N, Kassel J, Ng Y-S, Romero P, Friend SH. A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res 1992, 52, 6976-6978.
25. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83, 237-245.
26. Kulju KS, Lehman JM. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res 1995, 217, 336-345.
27. Afshari CA, Vojta PJ, Annab LA, Futreal PA, Willard TB, Barrett JC. Investigation of the role of G1/S cell cycle mediators in cellular senescence. Exp Cell Res 1993, 209, 231-237.
28. Atadja P, Wong H, Garkavtsev I, Geillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci USA 1995, 92, 8348-8352.
29. Bond JA, Blaydes JP, Bowson J, Haughton MF, Smith JR, Wynford-Thomas D. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/ WAFl. Cancer Res 1995, 55, 2404-2409.
30. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAFl/ p21 RNA in human cells. Mol Carcinogen 1994, 11, 59-64.
31. sdi1/cip1/wafl with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 1995, 10, 835-840.
32. Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T. Mol Cell Biol 1996, 16, 2402-2407.
33. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996, 271, 499-502.
34. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1 to S phase transition. Mol Cell Biol 1995, 15, 2612-2624.
35. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995, 83, 1149-1158.
36. Cip1. Oncogene 1995, 11, 1675-1683.
37. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994, 8, 666-677.
38. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumour growth and progression in vivo. Cell 1994, 78, 703-711.
39. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995, 81, 323-330.
40. Stein GH, Beeson M, Gordon L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science 1990, 249, 666-669.
41. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995, 11, 136-140.
42. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancers. Adv Cancer Res 1996, 68, 67-108.
43. DeLange T. Activation of telomerase in a human tumour. Proc Natl Acad Sci USA 1994, 91, 2882-2885.
44. Wynford-Thomas D, Bond JA, Wyllie FS, Jones CJ. Does telomere shortening drive selection for p53 mutation in human cancer? Mol Carcinogen 1995, 12, 119-123.
45. Bayne RA, Broccoli D, Taggert MH, Thomson EJ, Farr CJ, Cooke HJ. Sandwiching of a gene within 12kb of a functional telomere and alpha satellite does not result in silencing. Hum Mol Genet 1994, 4, 539-546.
46. Broccoli D, Godley LA, Donehower LA, Varmus HE, De Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol 1996, 16, 3765-3772.
47. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995, 92, 4818-4822.
48. Rubelj I, Pereira-Smith OM. SV40-transformed human cells in crisis exhibit changes that occur in normal cellular senescence. Exp Cell Res 1994, 211, 82-89.
49. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci USA 1988, 85, 6042-6046.
50. INK4 and telomerase in immortalisation of human cells. Oncogene 1995, 11, 971-976.
51. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995, 14, 4240-4248.
52. Whittaker NJ, Kidston EL, Reddel RR. Finite lifespan of hybrids formed by fusion of different simian virus 40-immortalised human cell lines. J Virol 1992, 66, 1202-1206.
53. Sandhu AK, Hubbard K, Kaur GP, Jha KK, Ozer HL, Athwal RS. Senescence of immortal human fibroblasts by the introduction of normal human chromosome 6. Proc Natl Acad Sci USA 1994, 91, 5498-5502.
54. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369, 574-578.
55. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995, 374, 386-388.
56. Wyllie FS, Haughton MF, Bond JA, Rowson JM, Jones CJ, Wynford-Thomas D. S phase cell-cycle arrest following DNA damage is independent of the p53/p21WAFl signalling pathway. Oncogene 1996, 12, 1077-1082.
57. Dimri GP, Nakanishi M, Desprez P-Y, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1996, 16, 2987-2997.
58. Smith JR, Nakanishi M, Robetorye RS, Venable SF, Pereira-Smith OM. Studies demonstrating the complexity of regulation and action of the growth inhibitory gene SDI1. Exp Gerontol 1996, 31, 327-335.
59. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 1996, 15, 1734-1741.
60. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996, 16, 2932-2939.
61. Loughran O, Malliri A, Owens D, et al. Association of CDKN2A/P16INK4a with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene 1996, 13, 561-568.
62. Klingelhutz AJ, Barber SA, Smith PP, Dyer K, McDougall JK. Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells. Mol Cell Biol 1994, 14, 961-969.
63. Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 1991, 65, 473-478.
64. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalised human mammary epithelial cells. J Virol 1991, 65, 6671-6676.
65. his). Oncogene 1996, 12, 715-725.
66. Wazer DE, Liu X-L, Chu Q, Gao Q, Band V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci USA 1995, 92, 3687-3691.
67. Shay JW, Tomlinson G, Piatyszek MA, Gollahon LS. Spontaneous in vitro immortalisation of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol 1995, 15, 425-432.
68. Shay JW, Van der Haegen BA, Ying Y, Wright WE. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 1993, 209, 45-52.
69. Van der Haegen BA, Shay JW. Immortalization of human mammary epithelial cells by SV40 large T-antigen involves a two step mechanism. In Vitro Cell Dev Biol 1993, 29A, 180-182.
70. Taylor-Papadimitriou J, Berdichevsky F, D'Souza B, Burchell J. Human models of breast cancer. In Lemoine NR, Wright NA, eds. The Molecular Pathology of Cancer. Cancer Surveys 16. Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press, 1993, 59-78.
71. Foster SC, Galloway DA. Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene 1996, 12, 1773-1779.
72. Bond JA, Ness GO, Rowson J, Ivan M, White D, Wynford-Thomas D. Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression. Int J Cancer 1996, 67, 563-572.
73. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond D, Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen 1993, 7, 83-88.
74. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237-1245.
75. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 1994, 9, 281-290.
76. Bond JA, Wyllie FS, Ivan M, Dawson T, Wynford-Thomas D. A variant epithelial sub-population in normal thyroid with high proliferative capacity in vitro. Mol Cell Endocrinol 1993, 93, 175-183.
77. Demers GW, Halbert CL, Galloway DA. Elevated wild-type p53 protein levels in human epithelial cell lines immortalised by the human papillomavirus type 16 E7 gene. Virology 1994, 198, 169-174.
78. Knight JC, Fletcher CDM. Soft Tissue Tumours. In Lemoine N, Neoptolemos J, Cooke T, eds. Cancer. Oxford, Blackwell Scientific, 1994, 262-275.
79. Stratton MR, Moss SD, Warren W, et al. Mutations of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 1990, 5, 1297-1301.
80. Nicholson RI, Gee JMW. Growth factors and modulation of endocrine response in breast cancer. In Vedeckis WV, ed. Hormones and Cancer. Boston, MA, Birkhauser, 1996, 227-264.
81. Thor AD, Moore II DH, Edgerton SM, et al. Accumulation of p53 tumor supressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992, 84, 845-855.
82. Mazars R, Spinardi L, BenCheikh M, et al. p53 mutations occur in aggressive breast cancer. Cancer Res 1992, 52, 3918-3923.
83. Portella G, Liddell J, Crombie R, et al. Molecular mechanisms of invasion and metastasis during mouse skin tumour progression. Invasion Metastasis 1994, 14, 7-16.
84. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim et Biophys Acta 1994, 1198, 11-26.
85. Williams DW, Williams ED. The pathology of follicular thyroid epithelial tumours. In Wynford-Thomas D, Williams ED, eds. Thyroid Tumours: Molecular Basis of Pathogenesis. Edinburgh, Churchill Livingstone, 1989, 57-65.
86. Wynford-Thomas D. Molecular genetics of thyroid cancer. Trends Endocrinol Metab 1993, 4, 224-232.
87. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 1996, 274, 373-376.